PURPOSE: Blast expression of CD56 is frequent in patients with t (8; 21)(q22; q22) acute
myeloid leukemia and is associated with an inferior outcome. The expression of CD56 has …

The biological significance of CD56 antigen expression in patients with acute promyelocytic
leukemia (APL) has been under investigation. We investigated the clinical and biologic …

The expression of CD56 antigen in acute promyelocytic leukemia (APL) blasts has been
associated with short remission duration and extramedullary relapse. We investigated the …

Expression of CD 56 has recently been introduced as one of the adverse prognostic factors
in acute promyelocytic leukemia (APL). However, the clinical significance of CD 56 antigen …

This study investigated the clinical characteristics and prognostic relevance of CD34
expression in 47 patients with acute promyelocytic leukemia (APL), showing t (15; 17) or …

PURPOSE: Preliminary reports suggest that leukemic cell expression of CD56, a neural cell
adhesion molecule, is associated with adverse clinical outcome in either acute myeloid …

Limited information is available on the relationship between expression of some additional
aberrant phenotypic features and outcome of acute promyelocytic leukemia (APL) patients …

Acute promyelocytic leukemia (APL) has a favorable prognosis. Current therapy includes
chemotherapy used in combination with all‐trans‐retinoic acid (ATRA). Although the …

BACKGROUND AND OBJECTIVES. CD56 antigen expression has been reported in several
hematologic malignancies. In acute myeloid leukemia (AML) M2 with t (8; 21) and acute …

CD56 expression in acute myeloid leukemia (AML) has been associated with
extramedullary leukemia and multidrug resistance, but its clinical and prognostic …